Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2006 by National Cheng-Kung University Hospital.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
National Cheng-Kung University Hospital
ClinicalTrials.gov Identifier:
NCT00336310
First received: June 12, 2006
Last updated: NA
Last verified: June 2006
History: No changes posted

June 12, 2006
June 12, 2006
July 2006
Not Provided
  • change of HbA1c at 12 weeks
  • Change of fasting plasma glucose (FPG) at 12 weeks
  • Change of postprandial plasma glucose (PPG) at 12 weeks
Same as current
No Changes Posted
  • Safety parameters including adverse events such as hypoglycemia
  • change of liver and renal function test
Same as current
Not Provided
Not Provided
 
A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients
A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients

The purpose of this study is to determine whether a new-brand of repaglinide is effective in the treatment of type 2 diabetes patients.

This study is designed to evaluate the efficacy and safety of a new-brand of repaglinide X® in comparison to Novonorm® for the treatment of type 2 diabetes mellitus patients. Mentally competent patients with age of 30 to 75 years old in Taiwan of either sex with type 2 diabetes mellitus will be included. All eligible subjects will be randomized into treatment groups in 1:1 ratio. The treatment will consist of either X® or Novonorm® tid before meal for 12 weeks of treatment. The primary endpoints include the net change of HbA!c, fasting plasma glucose(FPG)and postprandial plasma glucose(PPG)at the end of 12th week evaluation compared to the baseline visit. Also, safety profiles including adverse event (such as hypoglycemia) incidences, blood pressure, liver, kidney function test will be monitored.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
Drug: Repaglinide
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
50
Not Provided
Not Provided

Inclusion Criteria:

  • Mentally competent adults of either sex with age 30-75 years old
  • Patients have type 2 diabetes mellitus diagnosed after 25 years of age
  • Patients have been in poor glycemic control by diet or exercise for at least 1 month or by a stable dose of metformin for at least 3 months before study; poor glycemic control is defined as: Glycosylated hemoglobin A1c (HbA1c) 7.1-11.0%
  • Patients have signed the written informed consent form

Exclusion Criteria:

  • Patients with type 1 diabetes mellitus (insulin¬dependent)
  • Patients taking medications possibly to affect significantly the intestinal motility or the absorption of nutrients.
  • Female patients who are pregnant or trying to become pregnant or lactating during the study
  • Patients with alcohol, drugs or medications abuse considered by the investigator
  • Patients with impaired liver function (AST, ALT>2.5× upper limit of normal)
  • Patients with impaired kidney function (serum creatinine>3.0 mg/dl)
  • Patients with unstable cardiovascular conditions (e.g., New York Heart Association functional class III or IV congestive heart failure or a history of myocardial infarction or stroke)
  • Patients with emphysema or chronic bronchitis
  • Patients with diabetic ketoacidosis
  • Patients with hepatic cirrhosis
  • Patients with on-going inflammatory bowel disease, colonic ulceration, partial intestinal obstruction
  • Patients are predisposed to intestinal obstruction
  • Patients with chronic intestinal diseases related to marked disorders of digestion or absorption
  • Patients with clinically significant medical conditions that may deteriorate clinically due to gastrointestinal gas increase
  • Patients with a history of lactic acidosis
  • Patients with a history of allergic to repaglinide
  • Patients took any hypoglycemic agent except for metformin within 3 months before study
  • Patients participated investigational drug trial within 1 month before entering this study
  • Patients with any other serious diseases considered by the investigator not in the condition to enter the trial
Both
30 Years to 75 Years
No
Contact: H.Y. Ou, MD 886-6-2353535 ext 2177 wahoryi@mail.ncku.edu.tw
Contact: T.J. Wu, MD 886-6-2353535 ext 5387 djwu@mail.ncku.edu.tw
Taiwan
 
NCT00336310
YSRE0001
Not Provided
Not Provided
National Cheng-Kung University Hospital
Not Provided
Principal Investigator: T-J Wu, MD National Cheng-Kung University Hospital
National Cheng-Kung University Hospital
June 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP